Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease

Published:2023-04-20 Issue:9 Volume:66 Page:6082-6104
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ren Qiang¹²,Chen Ya¹,Zhou Zongtao¹³²⁴,Cai Zongyu¹,Jiao Shixuan¹²,Huang Wanqiu¹²,Wang Bin¹,Chen Siliang¹,Wang Wenxin¹²,Cao Zhijun¹²,Yang Zhongcheng¹,Deng Liming¹²,Hu Lijun¹,Zhang Luyong¹²⁴⁵,Li Zheng¹³²^ORCID

Affiliation:

1. School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China

2. Key Laboratory of New Drug Discovery and Evaluation of the Guangdong Provincial Education Department, Guangdong Pharmaceutical University, Guangzhou 510006, PR China

3. Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China

4. Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangdong Pharmaceutical University, Guangzhou 510006, PR China

5. Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, PR China

Funder

High-Level Clinical Key Specialty in Guangdong Province

Basic and Applied Basic Research of Guangzhou

National Key Clinical Specialty Construction Project

Guangxi Key Laboratory of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01918